Clearstead Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Clearstead Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$1.45K	–	2905
2025 Q1	$1.45K	Sell	11 -77	-88%	-$9.6K	﹤0.01%	1943
2024 Q4	$7.35K	Sell	88 -610	-87%	-$50.1K	﹤0.01%	1651
2024 Q3	$51.1K	Hold	698	–	–	﹤0.01%	1201
2024 Q2	$47.8K	Buy	+698	New	+$48.4K	﹤0.01%	1172

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Clearstead Advisors's ITCI Position: Q2 2025 in Review

Clearstead Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 11 shares — an estimated $1.45K sold.

Clearstead Advisors first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $51.1K in Q3 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Clearstead Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Clearstead Advisors sold 11 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.45K.
Clearstead Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Clearstead Advisors's Intra-Cellular Therapies Inc. position peaked at $51.1K in Q3 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Clearstead Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.